The role of dendritic cells in cancer

Morten Hansen; Mads Hald Andersen

doi:10.1007/s00281-016-0592-y

The role of dendritic cells in cancer

Morten Hansen^*, Mads Hald Andersen

^*Corresponding author for this work

37 Citations (Scopus)

Abstract

Though present in low numbers, dendritic cells (DCs) are recognized as major players in the control of cancer by adaptive immunity. The roles of cytotoxic CD8⁺ T-cells and Th1 helper CD4⁺ T-cells are well-documented in murine models of cancer and associated with a profound prognostic impact when infiltrating human tumors, but less information is known about how these T-cells gain access to the tumor or how they are primed to become tumor-specific. Here, we highlight recent findings that demonstrate a vital role of CD103⁺ DCs, which have been shown to be experts in cross-priming and the induction of anti-tumor immunity. We also focus on two different mediators that impair the function of tumor-associated DCs: prostaglandin E₂ and β-catenin. Both of these mediators seem to be important for the exclusion of T-cells in the tumor microenvironment and may represent key pathways to target in optimized treatment regimens against cancer.

Original language	English
Journal	Seminars in Immunopathology
Volume	39
Issue number	3
Pages (from-to)	307-316
ISSN	1863-2297
DOIs	https://doi.org/10.1007/s00281-016-0592-y
Publication status	Published - 1 Apr 2017

Keywords

Cancer
CD103
Dendritic cells
Immunology
PGE
β-catenin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00281-016-0592-y

Cite this

@article{72288d6799344e5fa615abdc2ac07f0f,

title = "The role of dendritic cells in cancer",

abstract = "Though present in low numbers, dendritic cells (DCs) are recognized as major players in the control of cancer by adaptive immunity. The roles of cytotoxic CD8+ T-cells and Th1 helper CD4+ T-cells are well-documented in murine models of cancer and associated with a profound prognostic impact when infiltrating human tumors, but less information is known about how these T-cells gain access to the tumor or how they are primed to become tumor-specific. Here, we highlight recent findings that demonstrate a vital role of CD103+ DCs, which have been shown to be experts in cross-priming and the induction of anti-tumor immunity. We also focus on two different mediators that impair the function of tumor-associated DCs: prostaglandin E2 and β-catenin. Both of these mediators seem to be important for the exclusion of T-cells in the tumor microenvironment and may represent key pathways to target in optimized treatment regimens against cancer.",

keywords = "Cancer, CD103, Dendritic cells, Immunology, PGE, β-catenin",

author = "Morten Hansen and Andersen, {Mads Hald}",

year = "2017",

month = apr,

day = "1",

doi = "10.1007/s00281-016-0592-y",

language = "English",

volume = "39",

pages = "307--316",

journal = "Seminars in Immunopathology",

issn = "1863-2297",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - The role of dendritic cells in cancer

AU - Hansen, Morten

AU - Andersen, Mads Hald

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Though present in low numbers, dendritic cells (DCs) are recognized as major players in the control of cancer by adaptive immunity. The roles of cytotoxic CD8+ T-cells and Th1 helper CD4+ T-cells are well-documented in murine models of cancer and associated with a profound prognostic impact when infiltrating human tumors, but less information is known about how these T-cells gain access to the tumor or how they are primed to become tumor-specific. Here, we highlight recent findings that demonstrate a vital role of CD103+ DCs, which have been shown to be experts in cross-priming and the induction of anti-tumor immunity. We also focus on two different mediators that impair the function of tumor-associated DCs: prostaglandin E2 and β-catenin. Both of these mediators seem to be important for the exclusion of T-cells in the tumor microenvironment and may represent key pathways to target in optimized treatment regimens against cancer.

AB - Though present in low numbers, dendritic cells (DCs) are recognized as major players in the control of cancer by adaptive immunity. The roles of cytotoxic CD8+ T-cells and Th1 helper CD4+ T-cells are well-documented in murine models of cancer and associated with a profound prognostic impact when infiltrating human tumors, but less information is known about how these T-cells gain access to the tumor or how they are primed to become tumor-specific. Here, we highlight recent findings that demonstrate a vital role of CD103+ DCs, which have been shown to be experts in cross-priming and the induction of anti-tumor immunity. We also focus on two different mediators that impair the function of tumor-associated DCs: prostaglandin E2 and β-catenin. Both of these mediators seem to be important for the exclusion of T-cells in the tumor microenvironment and may represent key pathways to target in optimized treatment regimens against cancer.

KW - Cancer

KW - CD103

KW - Dendritic cells

KW - Immunology

KW - PGE

KW - β-catenin

U2 - 10.1007/s00281-016-0592-y

DO - 10.1007/s00281-016-0592-y

M3 - Review

C2 - 27638181

AN - SCOPUS:84988427902

SN - 1863-2297

VL - 39

SP - 307

EP - 316

JO - Seminars in Immunopathology

JF - Seminars in Immunopathology

IS - 3

ER -

The role of dendritic cells in cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this